billHR8162•Event Monday, March 30, 2026Analyzed

To amend title 5, United States Code, to make certain modifications to how agencies conduct periodic reviews of agency rules, and for other purposes.

Neutral

Summary

HR8162 is an early-stage procedural bill that modifies federal agency rule review requirements. It authorizes no spending and targets no specific industry, making it a non-event for retail investors in the near term.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.HR8162 is a procedural bill with zero authorized spending and no industry-specific provisions.
2.The bill is in early stage, referred to two committees with only two cosponsors — low probability of near-term passage.
3.No retail investment implications; no companies or sectors are directly affected.

Market Implications

No market implications. This bill does not authorize spending, create tax incentives, impose regulations, or alter the competitive landscape for any sector or company. Retail investors should disregard HR8162 as a market signal.

Full Analysis

HR8162, the 'Regulatory Review Improvement Act of 2026', was introduced on March 30, 2026, and referred to the House Judiciary and Small Business committees. The bill amends 5 U.S.C. § 610 to require agencies to solicit public comments on whether rules should remain in effect, expand the factors considered in reviews (including cost of compliance and paperwork hours), and mandate qualitative and quantitative summaries of public comments. It is an early-stage procedural bill with no funding authorization and no direct targets on specific industries or sectors. The bill is sponsored by Rep. Meuser (R-PA), a junior member, with only two cosponsors, indicating low legislative momentum. As a procedural reform rather than a spending or regulatory bill, it does not create or redirect capital flows to any public companies. No dollar amounts are authorized or appropriated. The bill's impact on the regulatory process, if enacted, could marginally increase compliance costs for agencies, but it does not alter any existing rule or impose new obligations on private entities. Given its early stage, low sponsorship, and purely procedural nature, this bill is a non-event for markets. No tickers or sector impacts are warranted.